Mirum Pharmaceuticals insider buys and sells shares
© Reuters.
Mirum Pharmaceuticals, Inc. (NASDAQ:) Chief Development Officer, Lara Longpre, reported transactions in company stock, as disclosed in the latest SEC filings. Longpre purchased 965 shares at an average price of $10.64, totaling approximately $10,267. Additionally, a sale of 1,003 shares was executed at an average price of $20.6223, for a total value of around $20,684.
The purchase took place on September 10, 2019, and the shares were acquired within a price range of $10.20 to $10.8799. In a subsequent transaction on January 9, 2023, Longpre sold shares to cover tax withholding obligations related to the vesting of restricted stock units, as indicated by the footnotes in the filing.
Following these transactions, Longpre’s ownership in Mirum Pharmaceuticals stands at 104,369 shares. The company, which is part of the pharmaceutical preparations industry, is based in Foster City, California, and is incorporated in Delaware.
Investors and stakeholders in Mirum Pharmaceuticals often monitor insider transactions as they provide insights into how executives and significant shareholders are acting within the market. These transactions are public records and are regularly reported through SEC filings.
InvestingPro Insights
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been navigating a complex market environment, reflected in various financial metrics and analyst expectations. According to real-time data from InvestingPro, Mirum Pharmaceuticals has a market capitalization of $1.22 billion and is currently operating with a negative P/E ratio of -6.55, which further dipped to -7.47 over the last twelve months as of Q4 2023. Despite such challenging profitability indicators, the company’s revenue growth has been robust, with an increase of 141.85% over the same period.
InvestingPro Tips highlight that analysts have revised their earnings downwards for the upcoming period and do not anticipate the company to become profitable this year. This aligns with the company’s reported negative operating income margin of -58.57% and a substantial Return on Assets of -32.7% as of the last twelve months of Q4 2023. Nevertheless, Mirum Pharmaceuticals does have liquid assets that exceed its short-term obligations, which may provide some financial flexibility in the near term.
From an investment perspective, while the company has not been profitable over the last twelve months and does not pay a dividend, it has delivered a strong return over the last five years, with a 1-year price total return of 16.19%. The company’s stock is currently trading at 75.28% of its 52-week high, with a previous close price of $26.77.
For those seeking a deeper dive into Mirum Pharmaceuticals’ financial health and future prospects, there are additional InvestingPro Tips available at InvestingPro’s Mirum Pharmaceuticals page. With the use of the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking an array of comprehensive analytics and insights to inform their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
